EXANE DERIVATIVES: ANGO position timeline
Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of EXANE DERIVATIVES on ANGO, newest first. How the timeline and the estimate are built.
EXANE DERIVATIVES held 0 ANGO shares at 2022-03-31 per its 13F-HR filed 2022-04-22.
the latest 13F is the newest step
- period ended2022-03-3113F 0 sharesChange vs previous 13F -1,495 shares
13F-HR 0001623883-22-000004 filed by EXANE DERIVATIVES
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
Exited: the 13F for this period no longer lists the position.
- period ended2021-12-3113F 1,495 sharesChange vs previous 13F +1,465 shares
0.01% of the 13F portfolio, value $41,231.
13F-HR 0001623883-22-000002 filed by EXANE DERIVATIVES
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2021-09-3013F 30 sharesChange vs previous 13F -5,626 shares
<0.01% of the 13F portfolio, value $778.
13F-HR 0001623883-21-000008 filed by EXANE DERIVATIVES
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2021-06-3013F 5,656 sharesChange vs previous 13F -3,472 shares
0.04% of the 13F portfolio, value $155,197.
13F-HR 0001623883-21-000006 filed by EXANE DERIVATIVES
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2021-03-3113F 9,128 sharesChange vs previous 13F +1,245 shares
0.06% of the 13F portfolio, value $213,586.
13F-HR 0001623883-21-000004 filed by EXANE DERIVATIVES
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2020-12-3113F 7,883 sharesChange vs previous 13F not available
0.04% of the 13F portfolio, value $120,841.
13F-HR 0001623883-21-000002 filed by EXANE DERIVATIVES
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).